Tags : preclinical

Clinical Trials

Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study

Shots: Nektar presents two nonclinical data presentations for NKTR-255 at the 62nd ASH Annual Meeting, which include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farber Cancer Center NKTR-255 is being tested in a P-Ib/II study as monothx. & in combination with rituximab or daratumumab in patients with MM & […]Read More

M&A

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to

Shots: Shots: Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches” The first program is an Ab inhibitor of Periostin, which contributes to cancer […]Read More